Amgen Planning Pivotal Obesity Program For MariTide

MariTide Phase III Trials To Include Diabetes

May 02 2024

• By Mandy Jackson

Listen to this article

Executives said during Amgen’s Q1 call that the company is “encouraged” by interim Phase II data for MariTide (AMG 133) in obesity, so it is designing Phase III trials and building manufacturing capacity.

Professional nutritionist sitting at desk and writing a meal plan, measuring tape and apple — Phase III trials are planned in obesity, related conditions and diabetes • Source: Shutterstock

Amgen, Inc. revealed during its first quarter 2024 earnings call on 2 May that it will focus its research and development investment in obesity going forward largely on MariTide (maridebart cafraglutide, AMG 133) after a look at interim Phase II results for the GIP receptor antagonist/GLP-1 agonist and the completion of a Phase I trial for the obesity candidate AMG 786. Planning is under way for a multi-indication Phase III MariTide program, but development of AMG 786 is discontinued.

Key Takeaways

Amgen discontinued Phase I obesity candidate AMG 786, but said after an interim look at Phase II data for MariTide (AMG 133) it is planning a Phase III program for that drug.

“Across the portfolio, we are presently prioritizing differentiated medicines – those that stand to provide the greatest benefit for patients,”...

More from Alimentary/Metabolic

ProGen’s Dual Agonist Obesity Contender Gains Momentum With Rani Partnership
Dec 05 2025
• By Jung Won Shin
The CEO of South Korean biotech shares how his company was able to reach a partnership with Rani so quickly and why it is confident in its GLP-1/GLP-2 dual agonist for obesity and diabetes, despite recent disappointing clinical results for its sole rival.
Sciwind Eyes Differentiation For Ecnoglutide In Highly Competitive Arena
Dec 05 2025
• By Xu Hu
Chinese firm Sciwind has revealed additional Phase III findings for its promising once-weekly GLP-1 agonist ecnoglutide, just one asset in a burgeoning Chinese sector that could see the emergence of new rivals to current global leaders in obesity and diabetes.
Cagrisema Leads The Charge For 2025
Mar 10 2025
• By Elizabeth Cairns
2030 sales forecasts for Novo’s obesity hope are an order of magnitude larger than its closest rival among 2025’s expected debutantes.
Evidence Growing For GLP-1s To Treat Alzheimer’s And Parkinson’s
Mar 10 2025
• By Andrew McConaghie
GLP-1 receptor agonists could play a big role in tackling neurodegeneration and a new academic study has raised expectations of Novo Nordisk’s latest semaglutide Phase III results

More from Therapeutic Category

Scrip Data Article Without An Author
Nov 19 2025
"Neque porro quisquam est qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit..."
Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]
Nov 12 2025
Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.
Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC
Nov 12 2025
Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.